Approximately half the worldwide population is at risk for dengue. No antiviral prophylaxis or treatment options are available. In a phase 2a, double-blind, randomized trial, we assigned healthy ...

Biogen Inc. announced that the FDA has accepted and the EMA has validated its supplemental New Drug Application for a higher dose regimen of nusinersen, intended for treating spinal muscular atrophy ...